Aktienanalyse zu Exelixis Inc (EXEL)EXELExelixis Inc

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Exelixis Inc is currently priced at $64.53, which is above the average analyst target of $51. The RSI is at 73.003, indicating that the stock is overbought. Despite strong revenue growth and a gross margin of 96.71%, the recent FDA delay on a drug review until March 2027 poses a significant risk. Given these factors, it may be prudent to hold rather than buy at this time.

10 analysts cover EXEL: 6 rate it Buy, 4 Hold and 0 Sell. The average price target is 44.09.